MedTrace Logo

Long-Duration Stimulant Treatment Study of ADHD in Young Children

NCT00257725 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2020-08-26

Study results available
· View outcomes & findings →

Summary

This study will evaluate if Ritalin LA™ is safe and effective for ADHD treatment in 4-to-5-year olds.

Conditions

  • Attention Deficit Disorder With Hyperactivity

Interventions

DRUG

B-MPH

Dosage form is a 20 mg capsule to be given once daily in the morning for 30 days

Sponsors & Collaborators

  • New York State Psychiatric Institute

    lead OTHER

Principal Investigators

  • Laurence L Greenhill, MD · New York State Psychiatric Insitute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
4 Years
Max Age
5 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2008-03-31
Completion
2008-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00257725 on ClinicalTrials.gov